Cerebral palsy

H. Kerr Graham, Peter Rosenbaum, Nigel Paneth, Bernard Dan, Jean Pierre Lin, DIane L. Damiano, Jules G. Becher, Deborah Gaebler-Spira, Allan Colver, DInah S. Reddihough, Kylie E. Crompton, Richard L. Lieber

Research output: Contribution to journalReview article

  • 86 Citations

Abstract

Cerebral palsy is the most common cause of childhood-onset, lifelong physical disability in most countries, affecting about 1 in 500 neonates with an estimated prevalence of 17 million people worldwide. Cerebral palsy is not a disease entity in the traditional sense but a clinical description of children who share features of a non-progressive brain injury or lesion acquired during the antenatal, perinatal or early postnatal period. The clinical manifestations of cerebral palsy vary greatly in the type of movement disorder, the degree of functional ability and limitation and the affected parts of the body. There is currently no cure, but progress is being made in both the prevention and the amelioration of the brain injury. For example, administration of magnesium sulfate during premature labour and cooling of high-risk infants can reduce the rate and severity of cerebral palsy. Although the disorder affects individuals throughout their lifetime, most cerebral palsy research efforts and management strategies currently focus on the needs of children. Clinical management of children with cerebral palsy is directed towards maximizing function and participation in activities and minimizing the effects of the factors that can make the condition worse, such as epilepsy, feeding challenges, hip dislocation and scoliosis. These management strategies include enhancing neurological function during early development; managing medical co-morbidities, weakness and hypertonia; using rehabilitation technologies to enhance motor function; and preventing secondary musculoskeletal problems. Meeting the needs of people with cerebral palsy in resource-poor settings is particularly challenging.

LanguageEnglish (US)
Article number15082
JournalNature Reviews Disease Primers
Volume2
DOIs
StatePublished - Jan 7 2016

Fingerprint

Cerebral Palsy
Brain Injuries
Magnesium Sulfate
Hip Dislocation
Premature Obstetric Labor
Movement Disorders
Scoliosis
Human Body
Epilepsy
Rehabilitation
Newborn Infant
Technology
Morbidity
Research

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Graham, H. K., Rosenbaum, P., Paneth, N., Dan, B., Lin, J. P., Damiano, DI. L., ... Lieber, R. L. (2016). Cerebral palsy. Nature Reviews Disease Primers, 2, [15082]. https://doi.org/10.1038/nrdp.2015.82
Graham, H. Kerr ; Rosenbaum, Peter ; Paneth, Nigel ; Dan, Bernard ; Lin, Jean Pierre ; Damiano, DIane L. ; Becher, Jules G. ; Gaebler-Spira, Deborah ; Colver, Allan ; Reddihough, DInah S. ; Crompton, Kylie E. ; Lieber, Richard L. / Cerebral palsy. In: Nature Reviews Disease Primers. 2016 ; Vol. 2.
@article{a0b24a5f77c44a02b28b872aa71f2f77,
title = "Cerebral palsy",
abstract = "Cerebral palsy is the most common cause of childhood-onset, lifelong physical disability in most countries, affecting about 1 in 500 neonates with an estimated prevalence of 17 million people worldwide. Cerebral palsy is not a disease entity in the traditional sense but a clinical description of children who share features of a non-progressive brain injury or lesion acquired during the antenatal, perinatal or early postnatal period. The clinical manifestations of cerebral palsy vary greatly in the type of movement disorder, the degree of functional ability and limitation and the affected parts of the body. There is currently no cure, but progress is being made in both the prevention and the amelioration of the brain injury. For example, administration of magnesium sulfate during premature labour and cooling of high-risk infants can reduce the rate and severity of cerebral palsy. Although the disorder affects individuals throughout their lifetime, most cerebral palsy research efforts and management strategies currently focus on the needs of children. Clinical management of children with cerebral palsy is directed towards maximizing function and participation in activities and minimizing the effects of the factors that can make the condition worse, such as epilepsy, feeding challenges, hip dislocation and scoliosis. These management strategies include enhancing neurological function during early development; managing medical co-morbidities, weakness and hypertonia; using rehabilitation technologies to enhance motor function; and preventing secondary musculoskeletal problems. Meeting the needs of people with cerebral palsy in resource-poor settings is particularly challenging.",
author = "Graham, {H. Kerr} and Peter Rosenbaum and Nigel Paneth and Bernard Dan and Lin, {Jean Pierre} and Damiano, {DIane L.} and Becher, {Jules G.} and Deborah Gaebler-Spira and Allan Colver and Reddihough, {DInah S.} and Crompton, {Kylie E.} and Lieber, {Richard L.}",
year = "2016",
month = "1",
day = "7",
doi = "10.1038/nrdp.2015.82",
language = "English (US)",
volume = "2",
journal = "Nature Reviews Disease Primers",
issn = "2056-676X",
publisher = "Nature Publishing Group",

}

Graham, HK, Rosenbaum, P, Paneth, N, Dan, B, Lin, JP, Damiano, DIL, Becher, JG, Gaebler-Spira, D, Colver, A, Reddihough, DIS, Crompton, KE & Lieber, RL 2016, 'Cerebral palsy' Nature Reviews Disease Primers, vol. 2, 15082. https://doi.org/10.1038/nrdp.2015.82

Cerebral palsy. / Graham, H. Kerr; Rosenbaum, Peter; Paneth, Nigel; Dan, Bernard; Lin, Jean Pierre; Damiano, DIane L.; Becher, Jules G.; Gaebler-Spira, Deborah; Colver, Allan; Reddihough, DInah S.; Crompton, Kylie E.; Lieber, Richard L.

In: Nature Reviews Disease Primers, Vol. 2, 15082, 07.01.2016.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Cerebral palsy

AU - Graham, H. Kerr

AU - Rosenbaum, Peter

AU - Paneth, Nigel

AU - Dan, Bernard

AU - Lin, Jean Pierre

AU - Damiano, DIane L.

AU - Becher, Jules G.

AU - Gaebler-Spira, Deborah

AU - Colver, Allan

AU - Reddihough, DInah S.

AU - Crompton, Kylie E.

AU - Lieber, Richard L.

PY - 2016/1/7

Y1 - 2016/1/7

N2 - Cerebral palsy is the most common cause of childhood-onset, lifelong physical disability in most countries, affecting about 1 in 500 neonates with an estimated prevalence of 17 million people worldwide. Cerebral palsy is not a disease entity in the traditional sense but a clinical description of children who share features of a non-progressive brain injury or lesion acquired during the antenatal, perinatal or early postnatal period. The clinical manifestations of cerebral palsy vary greatly in the type of movement disorder, the degree of functional ability and limitation and the affected parts of the body. There is currently no cure, but progress is being made in both the prevention and the amelioration of the brain injury. For example, administration of magnesium sulfate during premature labour and cooling of high-risk infants can reduce the rate and severity of cerebral palsy. Although the disorder affects individuals throughout their lifetime, most cerebral palsy research efforts and management strategies currently focus on the needs of children. Clinical management of children with cerebral palsy is directed towards maximizing function and participation in activities and minimizing the effects of the factors that can make the condition worse, such as epilepsy, feeding challenges, hip dislocation and scoliosis. These management strategies include enhancing neurological function during early development; managing medical co-morbidities, weakness and hypertonia; using rehabilitation technologies to enhance motor function; and preventing secondary musculoskeletal problems. Meeting the needs of people with cerebral palsy in resource-poor settings is particularly challenging.

AB - Cerebral palsy is the most common cause of childhood-onset, lifelong physical disability in most countries, affecting about 1 in 500 neonates with an estimated prevalence of 17 million people worldwide. Cerebral palsy is not a disease entity in the traditional sense but a clinical description of children who share features of a non-progressive brain injury or lesion acquired during the antenatal, perinatal or early postnatal period. The clinical manifestations of cerebral palsy vary greatly in the type of movement disorder, the degree of functional ability and limitation and the affected parts of the body. There is currently no cure, but progress is being made in both the prevention and the amelioration of the brain injury. For example, administration of magnesium sulfate during premature labour and cooling of high-risk infants can reduce the rate and severity of cerebral palsy. Although the disorder affects individuals throughout their lifetime, most cerebral palsy research efforts and management strategies currently focus on the needs of children. Clinical management of children with cerebral palsy is directed towards maximizing function and participation in activities and minimizing the effects of the factors that can make the condition worse, such as epilepsy, feeding challenges, hip dislocation and scoliosis. These management strategies include enhancing neurological function during early development; managing medical co-morbidities, weakness and hypertonia; using rehabilitation technologies to enhance motor function; and preventing secondary musculoskeletal problems. Meeting the needs of people with cerebral palsy in resource-poor settings is particularly challenging.

UR - http://www.scopus.com/inward/record.url?scp=84985984445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84985984445&partnerID=8YFLogxK

U2 - 10.1038/nrdp.2015.82

DO - 10.1038/nrdp.2015.82

M3 - Review article

VL - 2

JO - Nature Reviews Disease Primers

T2 - Nature Reviews Disease Primers

JF - Nature Reviews Disease Primers

SN - 2056-676X

M1 - 15082

ER -

Graham HK, Rosenbaum P, Paneth N, Dan B, Lin JP, Damiano DIL et al. Cerebral palsy. Nature Reviews Disease Primers. 2016 Jan 7;2. 15082. https://doi.org/10.1038/nrdp.2015.82